Clinical trials: Crohn Disease in Remission
Crohn's Disease
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A in maintaining remission over 52 weeks in adult subjects with Crohn's…
- Trial name
- SHIELD-2 (NCT01316939)
- Testing
- GSK1605786A
- Where
- 256 sites in United States, Australia and 31 more
- Volunteers
- 229 people
- Sponsor
- GlaxoSmithKline
Crohn Disease (CD)
Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease. This study will investigate whether reducing the intake of ultra-processed foods through regular consultations with a registered dietitian can help children and adolescents…
- Trial name
- Up4-CD (NCT07884045)
- Testing
- Ultra-Processed Food Reduction Counseling, Standard Dietary Counseling
- Where
- 2 sites in Czechia
- Volunteers
- 124 people
- Sponsor
- University Hospital, Motol
Crohn's Disease
Thalidomide in Treating Crohn's Disease
Crohn's disease (CD) is a chronic gastrointestinal inflammatory disease characterized by relapse and progression. The incidence and prevalence of IBD are increasing in different regions around the world, indicating its emergence…
- Trial name
- NCT02501291
- Testing
- Thalidomide
- Where
- China
- Volunteers
- 47 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Crohn Disease
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
- Trial name
- NCT00295165
- Testing
- Sargramostim (Leukine)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 33 people
- Sponsor
- Genzyme, a Sanofi Company
Inflammatory Bowel Diseases
Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
Crohn's disease (CD) is a nonspecific chronic inflammatory condition characterized by a protracted course with alternating periods of relapse and remission.
- Trial name
- NCT07539727
- Testing
- Transabdominal Intestinal Ultrasound
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Crohn Disease
Stop Infliximab in Patients With Crohn's Disease
1 Project summary 1.1 Rational. Accent 1 study has demonstrated the superiority of Infliximab over placebo in a systematic treatment strategy of Crohn 's disease every 8 weeks during one year.
- Trial name
- STORI (NCT00571337)
- Testing
- Infliximab
- Where
- 23 sites in Belgium, France
- Volunteers
- 126 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Ustekinumab Serum Levels in Patients With Crohn´s Disease
Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.
A prospective, non-commercial, multicenter study will be conducted in a cohort of patients initiating induction therapy and a cohort of patients with stable treatment with ustekinumab.
- Trial name
- USTECRO (NCT07100093)
- Testing
- Drug serum levels
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario La Paz
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma
Crohn Disease
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index…
- Trial name
- NCT00552058
- Testing
- certolizumab pegol (CDP870, CZP)
- Where
- 116 sites in United States, Australia and 18 more
- Volunteers
- 439 people
- Sponsor
- UCB Pharma
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Crohn Disease
Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission
The purpose of this study is to determine whether infliximab can favourably and safely be discontinued in patients with Crohn's disease in sustained complete clinical, biochemical, and endoscopic remission on infliximab.
- Trial name
- STOP IT (NCT01817426)
- Testing
- Infliximab
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 115 people
- Sponsor
- Copenhagen University Hospital at Herlev
Crohn Disease, Inflammatory Bowel Diseases
Effect of Acupuncture on Patients With Crohn's Disease in Remission
To observe the therapeutic effect of acupuncture on Crohn's disease in remission and its influence of brain functional activity
- Trial name
- NCT04211129
- Testing
- acupuncture
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Crohn Disease
EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
A Phase 1, 2-part, multicentre study to evaluate the safety and preliminary efficacy of the oral administration of EXL01 in the maintenance of corticosteroid-induced clinical response/remission in participants with mild to…
- Trial name
- MAINTAIN (NCT05542355)
- Testing
- EXL01, SoC corticosteroid - Induction Period, SoC corticosteroid - Tapering
- Where
- 5 sites in Belgium, Poland
- Volunteers
- 8 people
- Sponsor
- Exeliom Biosciences
Crohn's Disease
Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease
The purpose of this study is to determine if high doses of vitamin D3 administered orally as adjunct therapy to children with Crohn's disease could improve the outcome of the disease.
- Trial name
- NCT01692808
- Testing
- Vitamin D3 3000 UI daily, Vitamin D3 4000 UI daily
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Justine's Hospital
Crohn's Disease
Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease
This clinical study is designed to evaluate the effect of Mediterranean diet as an add-on therapy for induction of remission in adult patients with active Crohn's disease and to evaluate its effects on clinical, inflammatory and…
- Trial name
- NCT02825316
- Testing
- Mediterranean diet, Low residue diet
- Volunteers
- 100 people
- Sponsor
- michal roll
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue
Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
The goal of this clinical trial is to learn if modafinil can treat severe fatigue in adults aged 18 to 75 years with quiescent inflammatory bowel disease (IBD).
- Trial name
- MODIFI-IBD (NCT07582458)
- Testing
- Modafinil
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Radboud University Medical Center